drugset / Trial / NCT00114686

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

NCT00114686

Phase 3 Completed 350 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether treatment with Quetiapine Fumarate (SEROQUEL) in conjunction with mood stabilizers (Lithium or Divalproex) for 12 weeks helps patients who have Bipolar I Disorder with Alcohol Dependence

Timeline

Start
2006-01
Primary completion
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule
Background Divalproex Sodium Small molecule
Background Lithium Unknown